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Abstract 
Background: Cardiac autonomic neuropathy (CAN) is a complication of diabetes 
mellitus (DM) that is associated with increased mortality. Exercise-based assessment of 
autonomic function has identified diminished parasympathetic reactivation after exercise 
in type 2 DM. It is postulated herein, that this would be more prominent among those 
with type 1 DM. 
Methods: Sixteen subjects with type 1 DM (age 32.9 ± 10.1 years), 18 subjects with type 
2 DM (55.4 ± 8.0 years) and 30 controls (44.0 ± 11.6 years) underwent exercise-based 
assessment of autonomic function. Two 16-min submaximal bicycle tests were performed 
followed by 45 min of recovery. On the 2nd test, atropine (0.04 mg/kg) was administered 
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near end-exercise so that all of the recovery occurred under parasympathetic blockade. 
Plasma epinephrine and norepinephrine levels were measured at rest, during exercise, and 
during recovery.  
Results: There were no differences in resting or end-exercise heart rates in the three 
groups. Parasympathetic effect on RR-intervals during recovery (p < 0.03) and heart rate 
recovery (p = 0.02) were blunted in type 2 DM. Type 1 DM had higher baseline 
epinephrine and norepinephrine levels (p < 0.03), and exhibited persistent 
sympathoexcitation during recovery.  
 
Conclusions: Despite a longer duration of DM in the study patients with type 1 versus 
type 2 DM, diminished parasympathetic reactivation was not noted in type 1 DM. 
Instead, elevation in resting plasma catecholamines was noted compared to type 2 DM 
and controls. The variable pathophysiology for exercise-induced autonomic abnormalities 
in type 1 versus type 2 DM may impact prognosis. 
Key words: cardiac autonomic neuropathy, diabetes mellitus, exercise testing, 
cardiac autonomic function 
 
 
INTRODUCTION 
Diabetes mellitus is an increasingly prevalent problem, with an estimated 
worldwide prevalence of 285 million people [1]. Longitudinal data from Framingham 
shows that approximately one-fifth of sudden cardiac deaths (SCDs) occurred in the 
setting of DM [2]. DM independently increases cardiovascular mortality as patients with 
DM without prior myocardial infarction or with preserved ejection fraction have the same 
event rates as nondiabetic patients with prior myocardial infarction [3] or with low (< 35–
40%) ejection fraction [4, 5], respectively. DM patients are at higher risk for SCD [6–13], 
even after adjustment for traditional risk factors such as coronary artery disease (CAD), 
hypercholesterolemia, and hypertension. The independent contribution of DM to cardiac 
mortality is thus well established. 
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials 
demonstrated that tight control of blood glucose, lipids, and hypertension may not 
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translate into improved survival [14–16], suggesting that other factors may be responsible 
for the increased mortality observed in patients with DM. Cardiac autonomic neuropathy 
(CAN) is a finding in DM with a prevalence that depends on the population studied and 
the diagnostic criteria used and is associated with an increased risk of SCD [17, 18], 
making it a potential target for treatment. The initial manifestations of CAN are thought 
to be due to diminished parasympathetic activity in the setting of preserved sympathetic 
tone [19, 20]. Because the risk for SCD is dramatically increased during periods of 
sympathoexcitation, such as related to exertion [21], an exercise-based assessment of 
parasympathetic effect was developed [22–26]. With exercise, there is a change from 
vagal predominance at rest to sympathetic predominance but not an absolute withdrawal 
of parasympathetic activity [24, 27]. A technique for exercise-based assessment uses 
parasympathetic blockade with atropine to assess the RR-interval in the presence and 
absence of cardiac parasympathetic input. With the exercise-based methodology, 
abnormalities in parasympathetic reactivation after exercise were identified in subjects 
with type 2 DM without overt CAN, as defined by the current diagnostic criteria [20]. 
Importantly, this abnormality appeared to be specific to diabetes, as it was not observed 
in a prior study of patients with CAD, even those with left ventricular dysfunction [26]. It 
was also demonstrated that the directional change in the QT interval (otherwise known as 
QT-RR hysteresis) is driven by changes in the parasympathetic nervous system during 
exercise and recovery [28], highlighting the role of the parasympathetic inputs on cardiac 
repolarization and providing a potential pathophysiologic link among diabetics, CAN, 
and the increased risk of SCD with exercise. 
It was therefore hypothesized herein, that an exercise-based assessment of 
cardiovascular autonomic inputs would also identify these abnormalities in asymptomatic 
subjects with type 1 diabetes, a population that has a higher rate of moderate to severe 
CAN than subjects with type 2 diabetes [29] and with longer resting QTc [30]. In 
addition, it was hypothesized that the extent and severity of CAN would differ between 
subjects with type 1 and type 2 diabetes given the differences in extent/duration of 
hyperglycemia in these patients, specifically that the population with type 1 diabetes 
would exhibit a more severe phenotype than those with type 2 diabetes, and that the 
primary abnormality would be a further reduction in parasympathetic effects during 
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exercise and recovery than was demonstrated previously in subjects with type 2 diabetes 
using an exercise-based assessment of autonomic function.  
 
METHODS 
Subjects 
 Group I included 30 healthy volunteers aged 18–70 years without a diagnosis of 
DM. All subjects in this group were free from significant medical conditions, were not 
taking cardioactive medications, and had normal physical examinations and 
electrocardiograms (ECG). Several of these volunteers were controls in a previous 
publication [20]. Group II included 16 volunteers with type 1 DM as defined by the 
American Diabetes Association report criteria and were phenotyped as having type 1 DM 
by experienced diabetologists [31]. Subjects were included if they had diabetes for > 1 
year, were on a stable insulin regimen for > 3 months, participated in aerobic exercise for 
> 60 min/week, and weighed < 90 kg and were excluded if they were taking beta-
blockers. Subjects with autonomic disorders, myocardial ischemia/infarction, heart 
failure, arrhythmias, and pacemakers were excluded. Patients with neuropathy, 
nephropathy, microalbuminuria,  retinopathy, or systemic illnesses such as asthma and 
renal insufficiency were also excluded. For comparison purposes, Group III included 18 
subjects with type 2 DM who were previously studied and reported on [20]. Subjects in 
this group had DM > 1 year, were on a stable medical regimen for 3 months. None were 
taking insulin. As in group II, these subjects were required to participate in regular 
cardiovascular exercise and could not be on beta-blocker medications. The study protocol 
for these subjects was identical to the current report, allowing a comparison of results in 
subjects with type 1 and type 2 diabetes. 
 
Peripheral neuropathy and CAN testing 
All subjects with a diagnosis of DM were screened with the Michigan Neuropathy 
Screening Instrument (MNSI) to assess for peripheral neuropathy on study visit one [32]. 
CAN was assessed this same day with a battery of 5 noninvasive cardiovascular reflex 
tests [33]. The tests, as previously described, included heart rate response to deep 
breathing, standing, and Valsalva maneuver, as well as blood pressure response to 
5 
 
standing and sustained handgrip. Results of these tests are referred to as the Ewing score; 
higher scores indicate more severe CAN. While subject enrollment was restricted to those 
without clinical evidence of peripheral neuropathy or CAN, the MNSI or Ewing score 
was not used to exclude subjects. 
 
Exercise testing 
All subjects underwent seated bicycle exercise testing on two days separated by ≥ 
72 hours. Subjects continued their usual insulin regimen (for those on insulin) and diet 
prior to the test and were asked to refrain from caffeine prior to the test. Subjects with 
insulin infusion pumps continued their usual insulin protocol in order to avoid 
hypoglycemia. When possible, subjects were studied at the same time of day. An 
intravenous catheter was inserted into an antecubital vein for blood draws and/or drug 
administration. Subjects were attached to an ECG machine (Burdick Quest Exercise 
Stress System, Cardiac Science, Bothell, WA). For subjects with diabetes, a blood sample 
was drawn for measurement of hemoglobin A1c, BUN, and creatinine levels. For all 
subjects, blood was drawn for measurement of plasma catecholamines at rest after 
assuming a seated resting position for ≥ 5 min. All subjects had normal resting blood 
pressures. All measurements were made with subjects seated on an electrically-braked 
bicycle ergometer (SciFit ProII, Tulsa, OK). Continuous 12-lead ECG monitoring was 
performed for a 5-min rest period, a 16-min exercise period, and a 45-min recovery 
period. Subjects were instructed to maintain a pedal speed of 80 rpm during all phases of 
the exercise session. The exercise protocol began at a 50-Watt workload, increased to 75 
Watts at 4 min and 100 Watts at 6 min, as tolerated. Subjects continued to exercise at this 
workload for an additional 10 min. At the end of 16 min of exercise, heart rate and blood 
pressure were recorded, and exercise was stopped. All subjects demonstrated the 
expected increase in heart rate and blood pressure with exercise with no evidence of 
ischemia. Blood samples were drawn for plasma catecholamine levels at 8 and 15 min of 
exercise, and minutes 5, 10, 20, 30, and 45 of recovery.  
On the second session, the identical protocol was performed. However, 
intravenous atropine (0.04 mg/kg) was administered in 4 divided doses (0.01 mg/kg every 
30 s) starting at 12 min of exercise to achieve complete parasympathetic blockade. 
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Parasympathetic blockade with atropine has a rapid onset, has been shown previously to 
last over 1 h, and is considered the gold standard for evaluation of parasympathetic 
effects [34, 35]. To ensure subject safety and ability to complete the exercise protocol, 
the first session was always performed without parasympathetic blockade and the second 
session was performed with parasympathetic blockade. 
 
Parasympathetic effect 
For each subject and at each time point in recovery, parasympathetic effect on the 
RR-interval was defined as the difference of the RR-interval (∆RR) at baseline without 
atropine and the RR-interval after parasympathetic blockade with atropine.  
 
Plasma catecholamines 
Blood samples were collected for epinephrine and norepinephrine levels in 
heparinized tubes and placed on ice. After centrifugation at 4ºC at 3000 rpm for 15 min, 2 
mL of plasma was transferred to an empty tube and stored at –70ºC for subsequent 
analysis. This sample was then transferred to Quest Diagnostics Laboratories with dry ice 
for analysis, as previously reported [20]. 
 
RR-intervals and heart rate recovery 
Electrocardiogram data were analyzed with custom software (MATLAB-
Mathworks, Natick, MA). Using a QRS template-matching algorithm, an interval 
tachogram was generated from the continuous ECG recording. All recordings were 
examined and manually overread to verify beat classification. Early heart rate recovery 
(EHRR) was calculated as end-exercise, exercise heart rate minus heart rate at 1 min of 
recovery. Late heart rate recovery (LHRR) was calculated as RR-interval at 5 min of 
recovery minus end-exercise RR-interval divided by RR-interval at rest minus RR-
interval at end-exercise multiplied by 100 [36]. 
 
Heart rate variability 
Heart rate variability analysis was performed on 5 min resting ECG recordings 
obtained prior to the initiation of exercise. The time domain parameters of root mean 
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square of successive differences (MSSD) and root mean square residuals of linearly 
detrended RR-intervals (RMS) were calculated for five consecutive 1-min periods during 
the initial resting period [37]. The five values were averaged for analysis. 
Frequency domain analysis was performed. The RR-intervals from these 
recordings were resampled at 4 Hz and then linearly detrended. After applying a Hanning 
window, the fast Fourier transform was used to obtain the power spectrum. Low 
frequency (LF) power was measured in the 0.04 to 0.15 Hz band while high frequency 
(HF) power was measured in the 0.15 to 0.5 Hz band [38].  
 
QT interval and indices of cardiac repolarization 
QRS onset was identified using slope threshold criteria. T wave offset was 
estimated as the point where the tangent of the maximum descending T wave slope 
intersected the isoelectric line. The median values of all leads were chosen as the global 
QRS onsets and T wave offsets for each beat from which QT intervals were calculated. 
All measurements were visually confirmed.  
Because of the changing heart rate throughout the protocol and differences 
between subject heart rates, comparison of cardiac repolarization parameters is 
challenging and a gold standard is lacking. It was therefore calculated that the QT-RR 
slope in recovery, which has been shown to be a more reliable description of 
repolarization in the setting of changing heart rates as compared to the QT interval [39]. 
The QT-RR slope was calculated for each subject using linear regression analysis from 6 
QT-RR-interval pairs (0–5 min) in early recovery, as this has been shown to have 
prognostic significance [40]. Baseline QTc values were also calculated using the Bazett 
formula. 
 
Statistics 
Comparisons between groups were performed with analysis of variance for 
continuous variables and χ2 tests for categorical variables. Data are presented as mean ± 
standard error and counts (%) in the demographic tables and for non-modeled data, 
including heart rate variability, baseline heart rates, end-exercise heart rates, heart rate 
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recovery, and baseline QTc. Natural logarithm transformation was used for 
norepinephrine data to better approximate normality. 
A repeated-measures mixed-effects model with random effects of subjects was 
used to analyze all other outcome data including parasympathetic effect, epinephrine 
level, norepinephrine level, and QT-RR slope. First-order auto-regressive variance-
covariance structure was used to model the correlations among measurements in time. 
Because of the age and sex differences among the groups, these factors were included in 
the analyses of autonomic effects. Thus, the fixed effects included age, sex, type of 
diabetes, parasympathetic blockade, their interaction, as well as time in recovery. As 
appropriate, exercise, early recovery and late recovery segments of the data were 
analyzed in separate independent models. In the presence of interactions with sex, males 
and females were also analyzed in separate models. A single extreme positive outlier 
value of epinephrine (> 600 pg/mL) was excluded from analyses. ANOVA was used to 
compare baseline characteristics among the three study groups where there are no 
measurements clustered within patients. Mixed effects models, on the other hand, were 
used in all cases with repeated measurements across time within patients. A p-value < 
0.05 was considered significant. Modeled effects are reported as mean ± standard error. 
All modeled effects are reported with adjustment for sex and age. Results for 
norepinephrine are represented as 95% confidence intervals (CI) as the model used 
logarithmic transformation. 
 
Study approval 
The study was approved by the Northwestern University Institutional Review Board. 
Written informed consent was required from all subjects prior to enrollment in the study. 
 
RESULTS 
Baseline characteristics 
Baseline characteristics are shown in Table 1. The 16 subjects with type 1 DM (4 
male, age 32.9 ± 10.2 years) were significantly younger than the 18 subjects with type 2 
DM that were previously studied [20] (12 male, age 55.4 ± 8.0 years). There were 30 
controls (15 male, age 44.0 ± 11.6 years). Subjects with type 1 diabetes had a mean 
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hemoglobin A1c of 7.1 ± 0.9% and average duration of diabetes of 18.6 ± 7.6 years, 
while subjects with type 2 diabetes had a mean hemoglobin A1c of 6.4 ± 0.7% (p < 0.02) 
and average duration of diabetes of 5.3 ± 4.0 years (p < 0.01). All subjects with type 1 
diabetes were on an insulin regimen, while no subject with type 2 diabetes was on insulin 
and 16 of the 18 subjects (89%) were taking metformin. Subjects with diabetes had no 
clinical evidence of peripheral or autonomic neuropathy and had low overall scores on 
CAN testing (Ewing score 0.8 ± 0.8 for type 1 DM and 1.2 ± 0.9 for type 2 DM, p = NS). 
Only 1 subject with type 1 diabetes demonstrated significant resting hypoglycemia on 
one of the visits. One subject with type 2 DM and 4 subjects with type 1 DM did not 
return for a second study visit and therefore data requiring two visits were excluded from 
analysis.  
 
Resting heart rate variability 
Root mean square of successive differences in type 2 DM (18.8 ± 9.4 ms) was 
lower than controls (29.4 ± 15.1 ms, p = 0.04) and type 1 DM (34.2 ± 20.7 ms, p = 0.09). 
Similarly, RMS was lower in type 2 DM (24.3 ± 10.0 ms, p = 0.03) than controls (34.6 ± 
13.1 ms) and type 1 DM (39.6 ± 19.8 ms, p = 0.01). However, when adjusted for age and 
sex these differences were not significant.  
Frequency domain analysis revealed that LF power was higher in type 1 DM (433 
± 99 ms2; p = 0.0015 by ANOVA) than in type 2 DM (110 ± 26 ms2; p = 0.0004) and 
controls (223 ± 38 ms2; p = 0.009). There was no statistically significant difference in HF 
power among groups (36 ± 8 ms2 in type 1 DM; 16 ± 5 ms2 in type 2 DM; 44 ± 18 ms2 in 
controls). 
 
Heart rate response to exercise 
Baseline heart rates were 73.1 ± 11.4 bpm in type 1 diabetes, 75.0 ± 11.2 bpm in 
type 2 diabetes, and 70.1 ± 6.0 bpm in controls. Subjects with type 1 diabetes exercised to 
a workload of 90.6 ± 18.0 Watts, achieving a heart rate of 128.3 ± 16.9 bpm. Subjects 
with type 2 diabetes exercised to a workload of 91.7 ± 12.1 Watts, achieving a heart rate 
of 128.9 ± 22.0 bpm. Controls exercised to a workload of 94.0 ± 15.9 Watts, achieving a 
heart rate of 127.0 ± 19.2 bpm. After parasympathetic blockade with atropine, end-
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exercise heart rate increased to 148.0 ± 13.2 bpm in type 1 diabetes, 145.6 ± 21.1 bpm in 
type 2 diabetes and 149.4 ± 14.8 bpm in controls. None of these parameters differed 
among groups. 
 
Parasympathetic effect on the RR-interval 
RR-intervals for diabetes (type 1 and type 2) and control groups during exercise 
and recovery, with and without parasympathetic blockade, are shown in Figure 1A. As 
previously reported, subjects with type 2 diabetes had a significantly shorter average RR-
interval during recovery versus controls. After parasympathetic blockade with atropine 
was achieved, the recovery RR-intervals curves are superimposable for the three groups.  
The parasympathetic effect, RR, in recovery is shown in Figure 1B and Table 2. 
When adjusted for age and sex, the increase in parasympathetic effect (RR) in early 
recovery was blunted in type 2 diabetes compared to type 1 diabetes (p = 0.03) and 
controls (p < 0.004), with no difference between type 1 diabetes and controls (p = 0.78). 
In later recovery (≥ 5 min), when adjusted for age and sex, the type 2 diabetes group had 
lower parasympathetic effect than controls (p < 0.002) with a trend for lower ∆RR than 
type 1 diabetes (p = 0.07) and no difference between type 1 diabetes and controls (p = 
0.53). Modeled estimates for ∆RR were 224.3 ± 12.7 ms for controls, 208.2 ± 23.0 ms for 
type 1 diabetes, and 145.6 ± 20.2 ms for type 2 diabetes.  
 
Plasma catecholamines 
Figure 2 shows the change in norepinephrine (NE) levels over time. Baseline NE 
levels were the highest for the type 1 diabetes group (800.6 pg/mL, 95% CI 646.8–990.8 
pg/mL) compared to both type 2 diabetes group (567.3 pg/mL, 95% CI 464.0–693.5 
pg/mL, p < 0.03) and controls (524.3 pg/mL, 95% CI 449.1–612.0 pg/mL, p < 0.01). 
There was no difference between controls and subjects with type 2 diabetes. Age had no 
effect on either baseline NE levels or NE change during exercise (p > 0.20); however, 
there was an interaction with sex (p = 0.02). There were no significant differences in end-
exercise NE levels or NE increase or recovery rates among the groups. When adjusted for 
age and sex, NE levels in later recovery (after 10 min recovery) remained elevated in type 
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1 DM compared to controls (p < 0.01) and type 2 DM (p < 0.03). There was no 
significant difference between subjects with type 2 diabetes and controls. 
Figure 2 also shows the change in epinephrine levels over time. Baseline 
epinephrine levels were elevated in type 1 diabetes (79.6 ± 7.0 pg/mL) compared to 
controls (56.6 ± 5.2 pg/mL, p < 0.03) and type 2 diabetes (37.5 ± 6.8 pg/mL, p < 0.01). 
There were no significant differences in end-exercise epinephrine levels or epinephrine 
increase or recovery rates among the groups. When adjusted for age and sex, epinephrine 
levels in later recovery (after 10 min recovery) remained elevated in type 1 diabetes 
compared to controls (p < 0.01) and type 2 diabetes (p < 0.01). There was no significant 
difference between type 2 diabetes and controls.  
 
Heart rate recovery 
Early heart rate recovery was highest in controls (26.4 ± 8.1 bpm), then in type 1 
diabetes (24.3 ± 10.0 bpm) followed by type 2 diabetes (19.1 ± 8.2 bpm). After 
adjustment for age and sex, EHRR was significantly lower only in type 2 diabetes 
compared to controls (p = 0.02). EHRR < 12 bpm was noted in 1 control, 3 subjects with 
type 1 diabetes, and 2 subjects with type 2 diabetes. Late heart rate recovery did not 
significantly differ among type 1 diabetes (64.5 ± 16.9%), controls (62.5 ± 16.9%), or 
type 2 diabetes (53.1 ± 18.6%, p = 0.14 for controls vs. type 2 diabetes). 
 
QT interval and QT-RR relationship 
QT intervals over time are shown in Figure 3. Baseline QTc did not differ among 
the groups: 412 ± 19 ms, 404 ± 19 ms, and 402 ± 21 ms in type 1 diabetes, type 2 
diabetes, and controls, respectively. The QT-RR slopes during early post-exercise 
recovery, calculated from 6 QT-RR pairs from 0–5 min of recovery were similar between 
all three groups (type 1 DM 0.26 ± 0.02, type 2 DM 0.25 ± 0.02, control 0.23 ± 0.02).  
 
DISCUSSION 
In this study, despite the substantially longer duration of diabetes in the study 
patients with type 1 (18.6 years) versus type 2 (5.3 years) diabetes, not only was the 
previously observed reduction in parasympathetic reactivation that was noted in type 2 
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diabetes not more prominent (as hypothesized), it was in fact absent. Instead, a significant 
basal increase in plasma catecholamines was noted compared to type 2 diabetes and 
controls. The fundamental differences in the autonomic profiles uncovered by this 
exercise-based assessment in these populations of patients with diabetes and minimal to 
no evidence of clinical peripheral or cardiac autonomic neuropathy are clear. If these 
exercise-based assessments apply more broadly to CAN in diabetes, this raises the 
possibility that the pathophysiology of CAN may not be uniform in subjects with type 1 
versus type 2 diabetes. While these abnormalities may produce a similar global shift in 
autonomic balance, the diagnostic, therapeutic, and prognostic implications of these 
heretofore undescribed differences require further exploration.  
 
Autonomic function  
In this study, several measures of autonomic function were assessed to delineate 
the spectrum of autonomic function changes observed in the population with diabetes. 
Resting measures included heart rate variability which evaluates the autonomic nervous 
system in the baseline state, a state of parasympathetic predominance. Reflex measures 
included the standard Ewing maneuvers which are designed to perturb the autonomic 
nervous system around an equilibrium point. Exercise measures, including plasma 
catecholamines, evaluate the autonomic nervous system during exercise, a time of 
sympathetic predominance and reduced parasympathetic activation. During recovery, 
parasympathetic effect and plasma catecholamines were assessed at a time of declining 
sympathetic effect and parasympathetic reactivation. This represents a broad snapshot of 
autonomic function across a spectrum of conditions. The currently, most clinically 
applied methodology for evaluation of CAN includes only the resting and reflex tests. 
The exercise testing approach used in this study represents a broader dynamic range of 
autonomic function and appears to be more sensitive for the detection of autonomic 
abnormalities in diabetes. Importantly, this exercise-based protocol was able to identify 
specific autonomic abnormalities that differed by diabetes type.  
 
Early CAN and ventricular repolarization in diabetes 
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This study demonstrated that subjects with type 1 diabetes exhibit increased 
sympathetic activation as manifest by elevated catecholamine levels while those with 
type 2 diabetes exhibit deficient parasympathetic reactivation after exercise as manifest 
by decreased parasympathetic effect on RR-intervals during recovery from exercise and 
decreased heart rate recovery. As the autonomic nervous system is characterized by the 
interplay of sympathetic and parasympathetic inputs, it is possible that the end result of 
either of these abnormalities is lengthening of ventricular repolarization (i.e. the QT 
interval), yet this was not observed in this study.  
While autonomic abnormalities were detectable in both type 1 and type 2 diabetes 
in the present study, these were not clinically apparent as this study, by design, enrolled a 
relatively healthy population of patients with diabetes. Specifically, all groups had similar 
and fairly normal resting heart rate and chronotropic response to exercise. The only 
abnormality detectable by routine exercise testing was diminished early heart rate 
recovery in subjects with type 2 diabetes. This suggests that the body’s compensatory 
mechanisms are able to accommodate for these early abnormalities, keeping them 
clinically silent. It is interesting that despite clear differences in sympathetic and 
parasympathetic function in the two groups of diabetics in this study, there were no clear 
differences in the resting QTc or recovery QT-RR relationships. This supports the notion 
that at this early stage, counterregulatory changes are occurring to maintain a relatively 
normal relationship. If this hypothesis can be verified, early treatment to prevent the 
progression of CAN may prevent or delay the development of cardiac repolarization 
abnormalities. Thus, early identification of these abnormalities could have prognostic and 
therapeutic significance. More importantly, it could provide a target for early treatment to 
prevent progression of disease and improve outcomes. A number of interventions have 
been associated with prevention and even reversal of early CAN [41–43], however this 
reversibility is not present in advanced disease. 
 
Pathophysiology of CAN in diabetes 
The pathophysiology of CAN in type 1 and type 2 DM has not been 
differentiated. Autonomic neuropathy has been thought to be due to hyperglycemic 
damage to the nerves, and CAN in type 1 and type 2 DM has been thought to be due to 
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the same pathophysiology, specifically that longstanding hyperglycemia leads to direct 
toxicity to the autonomic nerves. This concept led to the hypothesis that the study 
patients with type 1 diabetes would have more prominent abnormalities in 
parasympathetic reactivation after exercise due to the longer duration of diabetes 
compared to a previously studied population with type 2 DM. This study clearly refutes 
this hypothesis. While it is possible to speculate that patients with type 2 DM may have 
more subclinical cardiac disease which is responsible for the decline in parasympathetic 
effect, it should be noted that in prior studies no significant decline in parasympathetic 
effect was noted in patients with known CAD, with or without left ventricular 
dysfunction [26]. Thus, the reduced parasympathetic effect in type 2 DM is likely a 
specific finding for type 2 DM. The noted abnormalities in plasma catecholamines in the 
absence of a reduction in parasympathetic reactivation in type 1 DM raises the question 
about whether these entities have differing pathophysiology for the early phases of CAN. 
Further study is needed to more clearly differentiate CAN in subjects with type 1 and 
type 2 diabetes.  
 
Potential clinical implications 
Abnormalities in cardiac autonomic activity have been implicated in myriads of 
studies in risk for death and SCD. Moreover, diabetes is also independently associated 
with SCD risk [44]. Longitudinal data from Framingham show that approximately one-
fifth of SCDs occurred in the setting of DM [2]. Patients with DM are at higher risk for 
SCD [6–13], even after adjustment for traditional risk factors such as CAD, 
hypercholesterolemia, and hypertension. Given the known cardioprotective effects of 
parasympathetic tone and the adverse effects of sympathoexcitation, either of the 
abnormalities identified in the current study could theoretically contribute to the 
enhanced risk associated with diabetes. It is interesting that Treatment Of Preserved 
Cardiac function heart failure with an Aldosterone antagonist (TOPCAT) [45] identified 
diabetes as a risk factor for SCD in patients with heart failure and preserved ejection 
fraction, but this excess risk was only noted in insulin treated diabetics. Insulin has been 
shown to lead to increased sympathetic activity in both lean and obese subjects [46] and 
in animal studies [47]. In healthy women, insulin infusion during a euglycemic clamp 
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resulted in an increase in the LF/HF ratio consistent with sympathoexcitation. These data 
support the notion that either insulin use or type 1 diabetes may promote adverse 
sympathoexcitation that specifically increases the risk for SCD. 
 
Limitations of the study 
Limitations of the current study include the small sample size of the groups, as 
well as the inclusion/exclusion criteria that selected for a healthier group of subjects with 
diabetes. Age and sex differences among the groups were noted, but are unlikely to 
explain the marked differences. It is notable that the groups performed exercise to similar 
workloads and peak heart rate. Most importantly, the absence of abnormal 
parasympathetic reactivation in the study patients with type 1 diabetes remains a clear, 
unexpected, and novel observation. In addition, parasympathetic effect is calculated as 
the difference in RR-intervals between the baseline state and with atropine 
administration. These tests occurred on separate days and therefore there may be subtle 
differences that cannot completely be attributed to parasympathetic influence. The basic 
assumption for these studies is that the exercise response to a given workload is 
prototypical for any individual subject and that deviations in heart rate induced by 
selective autonomic blockade provides information on the autonomic contribution at that 
time. This is confirmed by the multiple studies [22–26] performed by the present group 
of researchers showing reproducible heart rate trends to various stages of exercise on 
different days prior to the administration of autonomic blockade.  
 
CONCLUSIONS 
In conclusion, the present subjects with type 1 and type 2 diabetes exhibited 
different abnormalities in exercise-based autonomic profiles. In this study, type 1 
diabetes was characterized by increased sympathoexcitation in the basal state and during 
recovery from exercise, while type 2 diabetes was characterized by decreased 
parasympathetic reactivation after exercise. This study suggests that CAN may differ 
between type 1 and type 2 diabetes. Further study is needed to determine the origin of 
these differences and whether this has prognostic or therapeutic implications, particularly 
16 
 
since cardiac autonomic neuropathy is associated with increased mortality in patients 
with diabetes. 
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Table 1. Subject characteristics. 
 
DM 1 (n = 16) DM 2 (n = 18) Control (n = 30) 
Age [years] 32.9 ± 10.2 55.4 ± 8.0 44.0 ± 11.6 
Male 25% 67% 50% 
Hypertension 25% 22% 0% 
Hyperlipidemia 25% 78% 10% 
Caucasian 94% 83% 60% 
Duration of diabetes [years] 18.6 ± 7.6 5.3 ± 4.0 NA 
MNSI Physical 0.08 ± 0.28 0.17 ± 0.18 NA 
MNSI History 0.46 ± 0.52 0.44 ± 0.41 NA 
Ewing score 0.78 ± 0.82 1.19 ± 0.94 NA 
Weight [kg] 73.7 ± 8.0 84.2 ± 8.3 76.2 ± 14.1 
Body mass index [kg/m2] 25.8 ± 3.2 28.5 ± 3.3 25.8 ± 3.0 
Creatinine [mg/dL] 0.72 ± 0.09 0.99 ± 0.25 NA 
Hemoglobin A1c (%) 7.1 ± 0.9 6.4 ± 0.7 NA 
Medications (%): 
   
Insulin 100% 0% 0% 
Metformin 0% 89% 0% 
ACEI  19% 22% 0% 
ARB 13% 6% 0% 
ASA 6% 56% 0% 
Statin 31% 67% 7% 
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; ASA — 
acetylsalicylic acid; DM 1 — type 1 diabetes mellitus; DM 2 — type 2 diabetes mellitus; MNSI — 
Michigan Neuropathy Screening Instrument 
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Table 2. Parasympathetic effect, ln(norepinephrine) and epinephrine values. 
 Parasympathetic effect [ms] ln (norepinephrine) [pg/mL] Epinephrine [pg/mL] 
 Controls Type 1 DM Type 2 DM Controls Type 1 DM Type 2 DM Controls Type 1 DM Type 2 DM 
Baseline    6.3 ± 0.08 6.7 ± 0.11 6.3 ± 0.10 56.6 ± 5.2 79.6 ± 7.0 37.5 ± 6.8 
Exercise (time)          
8 min    6.7 ± 0.08 6.9 ± 0.11 6.8 ± 0.10 66.2 ± 5.2 82.9 ± 7.1 49.7 ± 6.7 
Peak 76.7 ± 12.6 62.0 ± 20.0 58.4 ± 17.3 6.9 ± 0.08 7.0 ± 0.11 7.1 ± 0.10 80.5 ± 5.2 96.7 ± 7.0 67.9 ± 6.7 
Recovery (time):          
5 min 228.7 ± 12.6 218.9 ± 20.0 157.6 ± 17.3 6.6 ± 0.08 6.7 ± 0.10 6.8 ± 0.10 68.7 ± 5.2 76.7 ± 7.0 41.3 ± 6.7 
10 min 227.7 ± 12.6 195.4 ±20.0 164.2 ± 17.3 6.5 ± 0.08 6.7 ± 0.11 6.6 ±0.10 68.6 ± 5.2 85.9 ± 7.0 49.4± 6.7 
20 min 226.5 ± 12.6 191.0 ± 20.0 156.3 ± 17.3 6.4± 0.08 6.6 ± 0.10 6.5 ± 0.10 56.7 ± 5.1 91.6 ± 7.0 51.9 ± 6.6 
30 min 219.3 ± 12.6 196.0 ± 20.0 157.6 ± 17.3 6.4 ± 0.08 6.7 ± 0.11 6.4 ± 0.10 60.3 ± 5.2 88.4 ± 7.0 43.5 ± 6.6 
45 min 217.9 ± 12.6 186.6 ± 20.0 134.9 ± 17.3 6.4 ± 0.08 6.7 ± 0.11 6.5 ± 0.10 59.0 ± 5.2 79.7 ± 7.1 48.4 ± 6.6 
Values are presented as mean ± standard error. ln (norepinephrine) — natural logarithm of norepinephrine; DM — diabetes mellitus 
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Figure 1. In the top panel, RR-intervals are demonstrated at rest, during exercise, and in recovery for each group 
during the initial baseline test and the second test with administration of atropine. With exercise, RR-intervals 
decrease in each group, and with recovery RR-intervals increase in each group. RR-intervals are shortest in the type 
2 diabetes group during recovery. With atropine, the differences between groups are abolished, and RR-interval 
increase during recovery is blunted; the curves overlap for the three groups. In the bottom panel, parasympathetic 
effect on the RR-intervals is shown at end exercise and in recovery for each group, defined as the difference of the 
RR-interval (∆RR) at baseline without atropine and the RR-interval after parasympathetic blockade with atropine. 
Parasympathetic effect on RR-intervals during recovery is blunted in type 2 diabetes compared to controls and type 
1 diabetes; DM — diabetes mellitus. 
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Figure 2. Norepinephrine and epinephrine during rest, exercise, and recovery. Plasma norepinephrine and 
epinephrine concentrations at rest, during exercise, and in recovery for each group. Resting norepinephrine 
concentration is highest in those with type 1 diabetes. With exercise, norepinephrine increases in each group, 
however the decrease in norepinephrine is blunted in the type 1 diabetes group compared to the type 2 diabetes 
group and controls. Resting epinephrine concentration is highest in type 1 diabetes. With exercise, epinephrine 
increases in each group, however the decrease in epinephrine is blunted in the type 1 diabetes group compared to the 
type 2 diabetes group and controls; DM — diabetes mellitus. 
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Figure 3. QT intervals over time. QT intervals are demonstrated at rest, during exercise, and in recovery for each 
group during the initial baseline test and the second test with administration of atropine toward the end of exercise 
(see Figure 1A for figure legend). QT intervals decreased with exercise, and increased during recovery. QT intervals 
were shortest in the type 2 diabetes group during recovery. With atropine, the difference among groups was 
attenuated. 
 
 
 
 
